IR call - Acquisition of Ablynx

Sanofi will acquire Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®. Sanofi hosted a conference call & webcast on the acquisition for the financial community.

(14h30 CET / 8:30am ET)


Additional Information for US investors

The tender offer for the outstanding ordinary shares (“Shares”), American Depositary Shares issued by J.P. Morgan Chase Bank, N.A., acting as depositary (“ADSs”), warrants (“Warrants”) and convertible bonds of Ablynx (“Bonds” and, together with the Shares, ADSs and Warrants, the “Securities”) has not yet commenced. This communication is for informational purposes only and is neither a recommendation, an offer to purchase nor a solicitation of an offer to sell any Securities of Ablynx.
At the time the tender offer is commenced, Sanofi will file, or cause to be filed, a tender offer statement on Schedule TO with the SEC and thereafter, Ablynx will file a solicitation/recommendation statement on Schedule 14D-9. Holders of Securities are urged to carefully review the documents that will be filed by Sanofi and Ablynx with the SEC because these documents will contain important information, including the terms and conditions of the tender offer.
The offer to purchase, the related ADS letter of transmittal and certain other tender offer documents, as well as the solicitation/recommendation statement, will be available when filed to all holders of Securities of Ablynx at no expense to them. When filed these documents will be available for free at the rel="noopener noreferrer" SEC’s website at Additional copies may be obtained for free by contacting Sanofi at or on Sanofi’s website at


Call transcript


Press release - January 29, 2018: Sanofi to acquire Ablynx for €3.9 Billion